IL314205A - Ramibrutinib for use in the treatment of hidradenitis suppurativa - Google Patents

Ramibrutinib for use in the treatment of hidradenitis suppurativa

Info

Publication number
IL314205A
IL314205A IL314205A IL31420524A IL314205A IL 314205 A IL314205 A IL 314205A IL 314205 A IL314205 A IL 314205A IL 31420524 A IL31420524 A IL 31420524A IL 314205 A IL314205 A IL 314205A
Authority
IL
Israel
Prior art keywords
remibrutinib
treatment
hidradenitis suppurativa
suppurativa
hidradenitis
Prior art date
Application number
IL314205A
Other languages
English (en)
Hebrew (he)
Inventor
Souvik Bhattacharya
Bruno Bieth
Bruno Cenni
Gordon Graham
Michael Juhnke
Christian Loesche
Karin Rapp
Kim-Hien Sin
Jonas Benjamin Zierer
Original Assignee
Novartis Ag
Souvik Bhattacharya
Bruno Bieth
Bruno Cenni
Gordon Graham
Michael Juhnke
Christian Loesche
Karin Rapp
Sin Kim Hien
Jonas Benjamin Zierer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Souvik Bhattacharya, Bruno Bieth, Bruno Cenni, Gordon Graham, Michael Juhnke, Christian Loesche, Karin Rapp, Sin Kim Hien, Jonas Benjamin Zierer filed Critical Novartis Ag
Publication of IL314205A publication Critical patent/IL314205A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL314205A 2022-02-28 2023-02-27 Ramibrutinib for use in the treatment of hidradenitis suppurativa IL314205A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US202263369016P 2022-07-21 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
IL314205A true IL314205A (en) 2024-09-01

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314205A IL314205A (en) 2022-02-28 2023-02-27 Ramibrutinib for use in the treatment of hidradenitis suppurativa

Country Status (11)

Country Link
US (1) US20250099465A1 (cg-RX-API-DMAC10.html)
EP (1) EP4486346A1 (cg-RX-API-DMAC10.html)
JP (2) JP7696006B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240155278A (cg-RX-API-DMAC10.html)
CN (1) CN120617264A (cg-RX-API-DMAC10.html)
AU (1) AU2023225222A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251002A1 (cg-RX-API-DMAC10.html)
IL (1) IL314205A (cg-RX-API-DMAC10.html)
MX (1) MX2024010392A (cg-RX-API-DMAC10.html)
TW (1) TW202342048A (cg-RX-API-DMAC10.html)
WO (1) WO2023161887A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017089985A1 (en) 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
WO2018055550A1 (en) 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
CA3163850A1 (en) * 2020-01-08 2021-07-15 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
EP4284344A1 (en) 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition

Also Published As

Publication number Publication date
AU2023225222A1 (en) 2024-07-25
JP2025134747A (ja) 2025-09-17
MX2024010392A (es) 2024-09-06
EP4486346A1 (en) 2025-01-08
JP7696006B2 (ja) 2025-06-19
CN120617264A (zh) 2025-09-12
TW202342048A (zh) 2023-11-01
JP2024511938A (ja) 2024-03-18
WO2023161887A1 (en) 2023-08-31
CA3251002A1 (en) 2023-08-31
US20250099465A1 (en) 2025-03-27
KR20240155278A (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
TWI926143B (zh) 使用jak抑制劑治療化膿性汗腺炎
IL284338A (en) Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
IL306020A (en) Treatment of suppurative sweat gland inflammation with Orismilest
IL315901A (en) 5-MEO-DMT for use in the treatment of sleep disorders
IL315897A (en) 5-MEO-DMT for use in the treatment of sleep disorders
HRP20181598T1 (hr) Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
ES3066341T3 (en) Modified bont/a for use in the treatment of cervical dystonia
IL268569A (en) Treatment of hidradenitis suppurativa
IL307883A (en) HDAC6 inhibitors for use in the treatment of dilated myocardial disease
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
IL284307A (en) Methods for treating hidradenitis suppurativa using LTA4H
IL308134A (en) BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
HK40113828A (en) Remibrutinib for use in the treatment of hidradenitis suppurativa
EP4193995A4 (en) USE OF BTK INHIBITORS TO TREAT DISEASES
GB202002299D0 (en) Agents for use in the treatment of tissue damage
HK40107458A (en) Treatment of hidradenitis suppurativa with orismilast
ZA202100864B (en) Composition containing a 7beta-hydroxycholesterol and a lipid vehicle, and its use in the treatment of neoplastic pathologies
HK40053267A (en) Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
HK40099079A (en) Methods of treating hidradenitis suppurativa
GB202507093D0 (en) shRNA for use in the treatment of disease
CA3311000A1 (en) Lutikizumab for use in a treatment of hidradenitis suppurativa
HK40066571A (en) Anti-il-alpha antibody for the treatment of hidradenitis suppurativa
IL327100A (en) Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
IL315893A (en) 5-MEO-DMT for use in the treatment of postpartum depression
PL4522144T3 (pl) Kompozycja zawierająca kreatynę do stosowania w leczeniu trudności w oddychaniu